2009 - Fellow of the Royal Society, United Kingdom
His primary areas of study are Pathology, Lymphoma, MALT lymphoma, Mucosa-associated lymphoid tissue and B cell. His work on Lymphatic system, B-cell lymphoma and Immunohistochemistry as part of general Pathology study is frequently linked to Population, therefore connecting diverse disciplines of science. His work deals with themes such as Gastroenterology, Marginal zone and Virology, which intersect with Lymphoma.
His studies in MALT lymphoma integrate themes in fields like Carcinogenesis, Cancer research and Allele. He has included themes like Marginal zone B-cell lymphoma and Gastric lymphoma in his Mucosa-associated lymphoid tissue study. His B cell research is multidisciplinary, incorporating perspectives in T cell, Molecular biology and Lymphocyte.
Peter G. Isaacson mainly investigates Pathology, Lymphoma, MALT lymphoma, B cell and Lymphatic system. His study in the field of Mucosa-associated lymphoid tissue, Immunohistochemistry and B-cell lymphoma is also linked to topics like Population. His Lymphoma study incorporates themes from Stomach and Cancer research.
Peter G. Isaacson has researched MALT lymphoma in several fields, including BCL10 and Chromosomal translocation. His study in B cell is interdisciplinary in nature, drawing from both T cell, Gene rearrangement and Lymphocyte. His Antibody research is multidisciplinary, relying on both Molecular biology and Antigen.
Peter G. Isaacson focuses on Lymphoma, Pathology, MALT lymphoma, Immunology and Chromosomal translocation. His study in the field of BCL10 also crosses realms of Population. Peter G. Isaacson interconnects Gene rearrangement and Marginal zone in the investigation of issues within Pathology.
His study in MALT lymphoma is interdisciplinary in nature, drawing from both Cancer research and B cell. Peter G. Isaacson studied B-cell lymphoma and Mucosa-associated lymphoid tissue that intersect with Biopsy. Peter G. Isaacson does research in Lymphatic system, focusing on Gastric lymphoma specifically.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Immunoproliferative small-intestinal disease. An immunohistochemical study.
Peter G. Isaacson;Ahmet Dogan;Stephen K. Price;Jo Spencer.
The American Journal of Surgical Pathology (1989)
Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
A.C. Wotherspoon;T.C. Diss;L. Pan;P.G. Isaacson.
The Lancet (1993)
Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma
A.C. Wotherspoon;C. Ortiz-Hidalgo;M.R. Falzon;P.G. Isaacson.
The Lancet (1991)
Malignant lymphoma of mucosa‐associated lymphoid tissue. A distinctive type of B‐cell lymphoma
Peter Isaacson;Dennis H. Wright.
Cancer (1983)
The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori
T Hussell;P G Isaacson;J E Crabtree;J Spencer.
The Lancet (1993)
Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue.
Peter Isaacson;Dennis H. Wright.
Cancer (1984)
Malignant lymphoma of mucosa‐associated lymphoid tissue
P. G. Isaacson;J. Spencer.
Histopathology (1987)
Bcl10 Is Involved in t(1;14)(p22;q32) of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types
Tony G. Willis;Dalal M. Jadayel;Ming-Qing Du;Huaizheng Peng.
Cell (1999)
HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.
Nicolas Dupin;Tim L. Diss;Paul Kellam;Micheline Tulliez.
Blood (2000)
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases
S. A. Pileri;T. M. Grogan;N. L. Harris;P Banks.
Histopathology (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Memorial Sloan Kettering Cancer Center
Royal Marsden NHS Foundation Trust
King's College London
European Institute of Oncology
Medical University of Vienna
University of Leicester
World Resources Institute
University of Manchester
Medical University of Vienna
Charité - University Medicine Berlin
Université Catholique de Louvain
University of Geneva
Indian Institute of Technology Kharagpur
Shanghai University
University of Konstanz
University of Iowa
RMIT University
Leiden University
University of Tabriz
J. Craig Venter Institute
Spanish National Research Council
University of Rochester
University of Hawaii System
University of Missouri–Kansas City
University College London
Norwegian University of Science and Technology